Ivabradine Accord-Uk

Ivabradine, the active ingredient in Ivabradine Accord-Uk, is a If channel inhibitor presented as an oral formulation for oral use. It is used to lower heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction. GNH USA supplies Ivabradine Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction: improves symptoms and lowers risk of hospitalization by decreasing myocardial oxygen demand.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (resting heart rate <50 bpm) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Persistent visual impairment - Heart block or conduction abnormalities

Careful assessment and monitoring are required before and during therapy.

Monitor heart rate: ensure resting HR remains above 50 bpm. Avoid in severe hepatic impairment: use is contraindicated or requires dose adjustment. Caution in sick sinus syndrome: may exacerbate bradyarrhythmias. Do not combine with strong CYP3A4 inhibitors: risk of excessive drug exposure. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine may interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) - Other bradycardic agents (beta‑blockers, digoxin, verapamil) - Concomitant use with other If channel inhibitors

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (diltiazem, erythromycin) - Antihypertensive agents that may enhance heart‑rate lowering - Drugs affecting electrolyte balance (e.g., diuretics) that could predispose to arrhythmias